Compare INDB & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INDB | ARQT |
|---|---|---|
| Founded | 1907 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.3B |
| IPO Year | 1994 | 2020 |
| Metric | INDB | ARQT |
|---|---|---|
| Price | $78.38 | $21.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $87.00 | $34.00 |
| AVG Volume (30 Days) | 318.0K | ★ 1.2M |
| Earning Date | 04-16-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.32% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 1.63 | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $33.83 | $34.85 |
| Revenue Next Year | $5.85 | $29.39 |
| P/E Ratio | $48.00 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $59.61 | $12.72 |
| 52 Week High | $87.00 | $31.77 |
| Indicator | INDB | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 34.05 |
| Support Level | $76.77 | $19.60 |
| Resistance Level | $81.80 | $21.84 |
| Average True Range (ATR) | 1.54 | 1.15 |
| MACD | -0.01 | -0.25 |
| Stochastic Oscillator | 64.76 | 15.69 |
Independent Bank Corp is a bank holding company and the sole shareholder of its bank, the Rockland Trust Company. Rockland is a community-oriented commercial bank. The bank provides a variety of banking, investment and financial services, operating with various retail branches, as well as a network of commercial and residential lending centers and investment management offices majorly in Eastern Massachusetts, Worcester County, and Rhode Island. The bank's loan portfolio constitutes the bulk of the bank's total assets. Its borrowers consist mostly of small to medium-size businesses and consumers, majority of which are made to its market area in eastern Massachusetts and Rhode Island. The bank's loan portfolio is predominantly in commercial loans.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.